Phase III NALA: Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ MBC Previously Treated With HER2-Targeted Therapies

May 31 - June 4, 2019; Chicago, Illinois
Neratinib + capecitabine significantly prolonged PFS vs lapatinib + capecitabine (HR: 0.76) in patients with HER2+ MBC previously treated with at least 2 lines of therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 266 KB
Released: June 7, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Novartis Pharmaceuticals Corporation
Puma Biotechnology

Related Content

On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Gain key clinical insights quickly with this short slideset from CCO on the latest data on treatment for patients with HR+/HER2- early breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: July 9, 2021

Experts assess recurrence risk and use CDK4/6 inhibitors for HR+/HER2- early breast cancer in this on-demand webcast from a live Clinical Care Options (CCO) webinar

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue